Datopotamab Deruxtecan + Pembrolizumab
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non Small Cell Lung Cancer
Conditions
Metastatic Non Small Cell Lung Cancer
Trial Timeline
Mar 4, 2022 → Apr 30, 2028
NCT ID
NCT05215340About Datopotamab Deruxtecan + Pembrolizumab
Datopotamab Deruxtecan + Pembrolizumab is a phase 3 stage product being developed by Daiichi Sankyo for Metastatic Non Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05215340. Target conditions include Metastatic Non Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non Small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05215340 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Non Small Cell Lung Cancer